research 1465 Optimization/characterization of a Focal Dermal Hypoplasia mouse model to test potential treatments
Li2CO3 improved skin disease in a mouse model of Focal Dermal Hypoplasia without toxicity.
Search
for
Sort by
Research
330-360 / 1000+ results 
research Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research 341 A longitudinal study of cutaneous dermatomyositis
Most patients with cutaneous dermatomyositis either improved or remained stable over 3.5 years.
research Characterization of lipid profile in psoriasis, acne vulgaris, and androgenetic alopecia: a case–control study
Psoriasis, acne, and hair loss are linked to unhealthy cholesterol levels, increasing heart disease risk.
research Lipid profile in androgenetic alopecia
People with early-onset androgenetic alopecia may have a higher risk of heart disease due to abnormal blood lipid levels.
research Vitamin D deficiency in patients with alopecia areata: A systematic review and meta-analysis
Alopecia areata patients often have low vitamin D levels.
research Alopecia areata: A review
Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.
research Etiopathogenesis of Alopecia Areata
Alopecia Areata is an autoimmune condition causing hair loss, influenced by genetics, environment, and possibly improved by anti-MIF therapy, with many patients experiencing regrowth within a year.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research Effects of age and sex on the comorbidities of alopecia areata: A cross‐sectional hospital‐based study
Alopecia Areata is linked to a higher risk of several diseases, which vary with age and sex.
research Validity And Reliability of The Thai Version of The Family Dermatology Life Quality Index
The Thai version of the Family Dermatology Life Quality Index is a reliable and valid tool for assessing the quality of life of patients' families.
research Retrospective Analysis of Pediatric Alopecia Areata Treated with Methotrexate
Methotrexate may effectively and safely treat hair loss in children, with notable improvement after 12-15 months.
research Etiopathogenesis of alopecia areata: Why do our patients get it?
Alopecia areata is a skin condition causing hair loss, and its exact cause is unknown, but it may involve biological mechanisms.
research Management of alopecia areata: Updates and algorithmic approach
New treatments for alopecia areata show promise, but no cure exists and responses to treatments vary.
research Risk Factors for Premature Hair Graying in Young Turkish Adults
Premature hair graying in young Turkish adults is more likely if they have stress, a family history of graying, drink alcohol, have chronic diseases, are older, or are taller.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research Clinical and epidemiological characteristics and associated factors of hair graying: a population-based, cross-sectional study in Turkey
Most people in Turkey start getting gray hair around 33 years old, with factors like age, education, hair loss, skin type, family history, and anxiety playing a role.
research Selenium Toxicity in Domestic Animals
Selenium can be toxic to animals, causing serious health issues, especially in horses.
research Hereditary vitamin D-resistant rickets in Lebanese patients: the p.R391S and p.H397P variants have different phenotypes
Two different mutations in the vitamin D receptor gene cause different symptoms and responses to treatment in Lebanese patients with hereditary rickets.
research Prevalence of Hair Loss After COVID-19 Infection in Makkah Region, Saudi Arabia
Almost half of COVID-19 patients in Makkah, Saudi Arabia experienced increased hair loss, especially women and those with chronic diseases.
research COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.
research Association of resilience and perceived stress in patients with alopecia areata: A cross-sectional study
People with alopecia who are more resilient tend to feel less stressed.
research COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
Baricitinib works better than methotrexate for severe alopecia areata.
research Acne and Its Management
Effective acne treatment and patient education are crucial to prevent long-term physical and psychological effects.
research Limitations of Treatment-Induced Alopecia Grading Instruments in Evaluating Therapeutic Response
Current methods for grading hair loss from cancer treatment are not accurate enough and need improvement.
research Safety and efficacy of tofacitinib in 97 alopecia areata patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Alopecia areata multifocal grave – Um caso imagiológico
Severe alopecia areata in children can signal future autoimmune issues.
research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Is obesity surpassing the conventional risk factors in the development of CAD, irrespective of age?
Obesity is an independent risk factor for early coronary artery disease (CAD) and its severity is not affected by age.
research Diagnosis and treatment of alopecia areata
The document says how to diagnose and treat hair loss from alopecia areata, but there's no cure and treatments vary.